Apollomics Inc. regained compliance with the Nasdaq Capital Market's Market Value of Listed Securities (MVLS) requirement after maintaining a market value of $35 million or greater for 10 consecutive business days from June 23, 2026, to July 7, 2026. The company was previously non-compliant due to failure to meet the minimum $35 million threshold over a 30-day period. Apollomics Inc. is a biotechnology company focused on developing oncology treatments.